Chronic palmitoylethanolamide administration via slow-release subcutaneous pellets promotes neuroprotection and mitigates neuroinflammation in the Tg2576 mouse model of Alzheimer's disease
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Male Tg2576 mice, a genetic model of Alzheimer's disease, and normal littermates. About 8 to 11 per group, and fewer in some analyses.
- Dose used in the study
- About 30 mg/kg a day, released from a pellet implanted under the skin
- Duration
- 6 months, from 6 to 12 months of age
- What was measured
- Amyloid processing enzymes, activation of brain immune cells, inflammatory signals, oxidative damage, nerve cell spine density and a recognition memory test.
What the authors reported
An 8-fold fall in astrocyte activation and a 6-fold fall in oxidative protein damage in the hippocampus, less activation of microglia, restoration of nerve cell spine density to normal levels, and better recognition memory (novelty preference 57.5% against 44.5%). It also increased the amyloid-processing enzyme ADAM9, downregulated calcineurin, and shifted cytokine expression toward an anti-inflammatory profile (lower CXCL13, MCP-1 and GCSF; higher CXC3CL1 and IL-9).
Limits of this study
A mouse study in one genetic model, with only 2 to 4 animals in some analyses, which the authors name as a limit. Delivery was by an implant, not by mouth. One memory test was used. It does not show an effect in patients. Funding was not visible on the page checked.
Source
PubMed 40313591 · doi:10.3389/fncel.2025.1571428
Entry checked against the abstract on PubMed, and the full text at the publisher (Frontiers) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.